-
REAL-WORLD ADOPTION, BARRIERS, ARTIFICIAL INTELLIGENCE INTEGRATION, AND FUTURE READINESS OF ROBOTIC-ASSISTED SURGERY (RAS) IN CHINA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF GLP-1 RA TO PREVENT TYPE 2 DIABETES AMONG TEENAGERS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
EFFECT OF STATIN USE ON THE RISK OF ADVANCED LIVER DISEASE AND MORTALITY AMONG PATIENTS WITH CHRONIC LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Mar 18, 2026, 21:38 PM -
NEUROLOGICAL EFFECTS OF COMBINED EXPOSURE TO ORGANOPHOSPHATE AND PYRETHROID PESTICIDES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN US PATIENTS WITH 2L+ RECURRENT OR PROGRESSIVE ENDOMETRIAL CANCER (EC)
Mar 18, 2026, 21:38 PM -
LEARNING THE CAUSAL STRUCTURE OF MENTAL HEALTH LITERACY DIMENSIONS FROM OBSERVATIONAL DATA: A MULTI-METHOD CAUSAL DISCOVERY STUDY
Mar 18, 2026, 21:38 PM -
CLAIMS DATABASE ANALYSIS TO ASSESS THE COMPLEXITY AND SEVERITY OF PATIENT CASES, DISEASE BURDEN, AND HEALTH CARE RESOURCE UTILIZATION (HCRU) IN US BARTH SYNDROME PATIENTS
Mar 18, 2026, 21:38 PM -
BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
Mar 18, 2026, 21:38 PM -
FRAILTY AND INFLAMMATION AS PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING ELECTIVE CARDIAC SURGERY
Mar 18, 2026, 21:38 PM -
ASSESSING THE RETURN ON INVESTMENT (ROI) OF HEOR & RWE TO THE BIOPHARMACEUTICAL INDUSTRY: CASE EXAMPLE OF ECONOMIC MODELING IN HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
Mar 18, 2026, 21:38 PM -
REVIEW OF CEESP ICERS FOR ORPHAN AND NON-ORPHAN TREATMENTS IN FRANCE, 2024 - 2025
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF FITUSIRAN PROPHYLAXIS VERSUS FACTOR VIII ON-DEMAND OR PROPHYLACTIC THERAPY FOR HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Mar 18, 2026, 21:38 PM -
COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL VERSUS EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HEMOPHILIA A WITHOUT INHIBITORS IN COLOMBIA, PERU AND COSTA RICA
Mar 18, 2026, 21:38 PM -
INDIRECT TREATMENT COMPARISON OF ODEVIXIBAT AND MARALIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)
Mar 18, 2026, 21:38 PM -
USE OF NOVEL ELEMENTS OF VALUE IN COST-EFFECTIVENESS ANALYSES: INSIGHTS FROM THE CEA REGISTRY (2016-2024)
Mar 18, 2026, 21:38 PM -
BUDGETARY IMPLICATIONS OF REPLACING PATENTED SEVELAMER IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE IN MEXICO
Mar 18, 2026, 21:38 PM -
QUALITY OF LIFE AND PRODUCTIVITY LOSS COSTS OF NERVE BLOCK WITH DEEPLY INSERTED ACUPOTOMY VERSUS NERVE BLOCK ALONE IN LUMBOSACRAL RADICULOPATHY
Mar 18, 2026, 21:38 PM -
THE ROLE OF TRANSFER LEARNING ON THE PERFORMANCE OF MACHINE LEARNING MODELS ACROSS RACIAL/ETHNIC GROUPS
Mar 18, 2026, 21:38 PM -
ECOA METATEXT DEVELOPMENT: AN ESSENTIAL STEP IN MAINTAINING UX/UI ACROSS ALL LANGUAGES IN ECOA SOLUTIONS
Mar 18, 2026, 21:38 PM -
ASSESSING THE RETURN ON INVESTMENT (ROI) OF HEOR & RWE TO THE BIOPHARMACEUTICAL INDUSTRY: CASE EXAMPLE OF COMPARATIVE EFFECTIVENESS RESEARCH USING SECONDARY RWD SOURCES
Mar 18, 2026, 21:38 PM
